MorphoSys, a biotech that has spent much of its three-decade history developing drugs that ended up at other companies via partnerships or licensing deals, is now building up its own pipeline through ...
Conference call and webcast (in English) tomorrow, March 14, 2019 at 2:00pm CET (1:00pm GMT/9:00am EDT) - Interim data from all patients enrolled in ongoing L-MIND trial of MOR208 in combination with ...
Human Immunology Biosciences (HIBio) is a biotechnology company focused on developing precision medicines for autoimmune and inflammatory diseases, backed by ARCH Venture Partners and Monograph ...
MorphoSys Announces That Its Patents Were Ruled Invalid in Patent Lawsuit Against Janssen and Genmab
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / January 26, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) announces that it was informed today that in its lawsuit against ...
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) announced today that it has received a milestone payment from Novartis in connection with the initiation of a phase 1 clinical trial ...
Novartis is building up its pipeline of cancer therapies with the acquisition of MorphoSys, a company whose lead drug is on track for an FDA submission for the treatment of myelofibrosis. But the €2.7 ...
MorphoSys has found a home for a couple of assets it doesn’t want anymore—a nice billion-dollar home, that is—as the German biotech shifts focus to oncology. The company announced aftermarket Tuesday ...
MorphoSys AG (NASDAQ:MOR) is reportedly facing a burgeoning safety concern surrounding pelabresib, an experimental myelofibrosis treatment. Myelofibrosis is a type of blood cancer characterized by the ...
Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: Logo is seen at new factory of Novartis in Stein BERLIN (Reuters) -Novartis said on Thursday it has launched a tender ...
Novartis said Monday that it intends to buy MorphoSys for just under $3 billion. The deal will not close. Six months from now, or sooner, Novartis will walk away — slightly embarrassed but otherwise ...
Combination of Proprietary Drug Targets and Unique Technologies to Create Range of New Therapeutic Antibodies MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) and Galapagos NV (Euronext: GLPG) ...
PLANEGG/MUNICH, Germany & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--MorphoSys AG (FSE: MOR; NASDAQ: MOR) and Human Immunology Biosciences, Inc. (HIBio), a South San Francisco-based biotechnology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results